Lysophosphatidylcholine decreases locomotor activities and dopamine turnover rate in rats

NeuroToxicology

Volumn 26, Issue 1, 2005, Pages 27-38

  Lee, Eun Sook Y ^a   Soliman, Karam F A ^a   Charlton, Clivel G ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Dopamine; Locomotor activity; Lysophosphatidylcholine; Methylation; Parkinson's disease; S adenosylmethionine

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 3,4 DIHYDROXYPHENYLACETIC ACID; BIOGENIC AMINE; DOPAMINE; HOMOVANILLIC ACID; LYSOPHOSPHATIDYLCHOLINE; MEPACRINE; PHOSPHOLIPASE A2 INHIBITOR; S ADENOSYLMETHIONINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; EVALUATION; HYPOKINESIA; INJECTION; LATERAL BRAIN VENTRICLE; LOCOMOTION; MALE; NEUROPROTECTION; NONHUMAN; OBSERVATION; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TURNOVER TIME;

ANIMALS; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DOPAMINE; HYPOKINESIA; KINETICS; LIVER; LYSOPHOSPHATIDYLCHOLINES; MALE; METHYLTRANSFERASES; MOTOR ACTIVITY; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; PYRIDINIUM COMPOUNDS; QUINACRINE; RATS; RATS, SPRAGUE-DAWLEY; S-ADENOSYLMETHIONINE; SEROTONIN;

RODENTIA;

EID: 7444257993     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2004.07.009     Document Type: Article

References (56)

1. K. Aoyama, K. Matsubara, K. Okada, S. Fukushima, K. Shimizu, S. Yamaguchi, T. Uezono, M. Satomi, N. Hayase, S. Ohta, H. Shiono, and S. Kobayashi N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test J. Neural Transm. 107 2000 985 995
2. K. Aoyama, K. Matsubara, M. Kondo, Y. Murakawa, M. Suno, K. Yamashita, S. Yamaguchi, and S. Kobayashi Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease Neurosci. Lett. 298 2001 78 80
3. H.R. Arias The high-affinity quinacrine binding site is located at a non-annular lipid domain of the nicotinic acetylcholine receptor Biochim. Biophys. Acta 1347 1997 9 22
4. R.S. Burns, C.C. Chiueh, S.P. Markey, M.H. Ebert, D.M. Jacobowitz, and I.J. Kopin A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Proc. Nat. Acad. Sci. U.S.A. 80 1983 4546 4550
5. 2 and secretion of catacholamines from brain synaptosomes by potassium and A 23187 J. Neurochem. 41 1983 1684 1693
6. C.G. Charlton, and J. Mack Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain Mol. Neurobiol. 9 1994 149 161
7. M. Chiariello, G. Ambrosio, M. Cappelli-Bigazzi, E. Nevola, P. Perrone-Filardi, G. Marone, and M. Condorelli Inhibition of ischemia-induced phospholipase activation by quinacrine protects jeopardized myocardium in rats with coronary artery occlusion J. Pharmacol. Exp. Ther. 241 1987 560 568
8. M. Chiariello, G. Amrosio, M. Cappelli-Bigazzi, P. Perrone-Filardi, I. Tritto, E. Nevola, and P. Golino Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion Am. Heart J. 120 1990 801 807
9. C.C. Chiueh, S.P. Markey, R.S. Burns, J.N. Johannessen, A. Pert, and I.J. Kopin Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat Eur. J. Pharmacol. 100 1984 189 194
10. M.A. Collins, E.J. Neafsey, K. Matsubara, R.J. Cobuzzi Jr., and H. Rollema Indole-N-methylated beta-carbolinium ions as potential brain-bioactivated neurotoxins Brain Res. 570 1992 154 160
11. B.G. Crowell Jr., R. Benson, D. Shockley, and C.G. Charlton S-Adenosyl-l-methionine decreases motor activity in the rat: similarity to Parkinson's disease-like symptoms Behav. Neural Biol. 59 1993 186 193
12. +) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat Neurosci. Lett. 161 1993 121 123
13. N.H. Dubin, D.A. Blake, M.C. DiBlasi, T.H. Parmley, and T.M. King Pharmacokinetic studies on quinacrine following intrauterine administration to Cynomolgus monkeys Fertil. Steril. 38 1982 735 740
14. 2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion Brain Res. 752 1997 203 208
15. D.A. Gearhart, E.J. Neafsey, and M.A. Collins Characterization of brain β-carboline-2-N-methyltransferase, an enzyme that may play a role in idiopathic Parkinson's disease Neurochem. Res. 22 1997 113 121
16. F. Hirata, O. Viveros, E.J. Diliberto, and J. Axelrod Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine Proc. Natl. Acad. Sci. U.S.A. 75 1978 1718 1721
17. O. Hornykiewicz Dopamine (3-hydroxytyramine) and brain function Pharmacol. Rev. 18 1966 925 964
18. N.P. Hurst, J.K. French, A.L. Bell, G. Nuki, M.L. O'Donnell, W.H. Betts, and L.G. Cleland Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes Biochem. Pharmacol. 35 1986 3083 3089
19. Y. Ikeuchi, T. Nishizaki, T. Matsuoka, and K. Sumikawa Long-lasting enhancement of cholinergic receptor currents by lysophospholipids Brain Res. Mol. Brain Res. 45 1997 317 320
20. D.A. Johnson, and S. Ayres Quinacrine noncompetitive inhibitor binding site localized on the Torpedo acetylcholine receptor in the open state Biochemistry 35 1996 6330 6336
21. J.H. Kabarowski, K. Zhu, L.Q. Le, O.N. Witte, and Y. Xu Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A Science 293 2001 702 705
22. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
23. S. Lavielle, J.P. Tassin, A.M. Thierry, G. Blanc, D. Herve, C. Barthelemy, and J. Glowinski Blockade by benzodiazepines of the selective high increase in dopamine turnover induced by stress in mesocortical dopaminergic neurons of the rat Brain Res. 168 1979 585 594
24. +) increases S-adenosyl-l-methionine dependent phospholipid methylation Pharmacol. Biochem. Behav. 70 2001 105 114
25. E.Y. Lee, H. Chen, K.R. Shepherd, N.S. Lamango, Soliman KFA, and C.G. Charlton The inhibitory role of methylation on the binding characteristics of dopamine receptors and transporter J. Neurosci. Res. 48 2004 335 344
26. E.Y. Lee, H. Chen, K.R. Shepherd, N.S. Lamango, K.F.A. Soliman, and C.G. Charlton Inhibitory effects of lysophosphatidylcholine on the dopaminergic system Neurochem. Res. 29 2004 1333 1342
27. C.A. Lowry, K.J. Renner, and F.L. Moore Catecholamines and indoleamines in the central nervous system of a urodele amphibian: a microdissection study with emphasis on the distribution of epinephrine Brain Behav. Evol. 48 1996 70 93
28. K. Magishi, J. Kimura, Y. Kubo, and Y. Abiko Exogenous lysophosphatidylcholine increases non-selective cation current in guinea-pig ventricular myocytes Pflugers Arch. 432 1996 345 350
29. J. Maksem, N. Jacobson, and D.H. Neiderhiser Lysophosphatidylcholine- induced gastric injury and ulceration in the guinea pig Am. J. Pathol. 115 1984 288 295
30. 2-terminal extremity of SIV/HIV fusogenic proteins Biochim. Biophys. Acta 1240 1995 95 100
31. K. Matsubara, T. Gonda, H. Sawada, T. Uezono, Y. Kobayashi, T. Kawamura, K. Ohtaki, K. Kimura, and A. Akaike Endogenously occurring β-carboline induces Parkinsonism in non-primate animals: a possible causative pro-toxin in idiopathic Parkinson's disease J. Neurochem. 70 1998 727 735
32. 2 from rat neuronal cells and its possible function in the regulation of catecholamine secretion Biochem. J. 318 1996 701 709
33. K.S. McNaught, U. Thull, P.A. Carrupt, C. Altomare, S. Cellamare, A. Carotti, B. Testa, P. Jenner, and C.D. Marsden Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration Biochem. Pharmacol. 51 1996 1503 1511
34. M. Miele, G. Esposito, R. Migheli, S. Sircana, D. Zangani, G.L. Fresu, and M.S. Desole Effects of allopurinol on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced neurochemical changes in the striatum and in the brainstem of the rat Neurosci. Lett. 183 1995 155 159
35. 2 Science 216 1982 305 307
36. M. Naoi, W. Maruyama, T. Niwa, and T. Nagatsu Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin J. Neural Transm. Suppl. 41 1994 197 205
37. 2-treated presynaptic membranes in vitro Biochem. J. 318 1996 981 987
38. Y. Nishizuka Protein kinase C and lipid signaling for sustained cellular responses FASEB J. 9 1995 484 496
39. C.R. Oliveira, E.P. Duarte, and A.P. Carvalho Effect of phospholipase digestion and lysophosphatidylcholine on dopamine receptor binding J. Neurochem. 43 1984 455 465
40. M.H. O'Regan, M. Smith-Barbour, L.M. Perkins, and J.W. Phillis Arachidonic acid and lysophosphatidylcholine modulate excitatory transmitter amino acid release from the rat cerebral cortex Neurosci. Lett. 193 1995 85 88
41. A.R. Poole, J.I. Howell, and J.A. Lucy Lysolecithin and cell fusion Nature 227 1970 810 814
42. M.T. Quinn, S. Parthasarathy, and D. Steinberg Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis Proc. Natl. Acad. Sci. U.S.A. 85 1988 2805 2809
43. B. Scatton, F. Javoy-Agid, L. Rouquier, B. Dubois, and Y. Agid Reduction of cortical dopamine, noradrenalin, serotonin and their metabolites in Parkinson's disease Brain Res. 275 1983 321 328
44. G. Selby Parkinson's disease P.J. Vinken Handbook of clinical neurology. Disease of the basal ganglia 1975 173 211
45. O.Z. Sellinger, C.M. Kramer, A. Conger, and G.S. Duboff The carboxylmethylation of cerebral membrane-bound proteins increases with age Mech. Ageing Dev. 43 1988 161 173
46. W.T. Shier, J.H. Baldwin, M. Nilsen-Hamilton, R.T. Hamilton, and N.M. Thanassi Regulation of guanylate and adenylate cyclase activities by lysolecithin Proc. Natl. Acad. Sci. U.S.A. 73 1976 1586 1590
47. Slomiany BL, Jerzy-Glass GB, Kojima K, Banas-Gruszka Z, Slomiany A. Effect of lysolecithin on the constituents of gastric mucus. In: Chantler N, Elder JB, Elstein M., editors. International symposium on mucus in health and disease; 1981. p. 163-74.
48. M. Tariq, H.A. Khan, K. Al Moutaery, and S. Al Deeb Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents Brain Res. 54 2001 77 82
49. F. Thies, M.C. Delachambre, M. Bentejac, M. Lagarde, and J. Lecerf Unsaturated fatty acids esterified in 2-acyl-l-lysophosphatidylcholine bound to albumin are more efficiently taken up by the young rat brain than the un-esterified form J. Neurochem. 59 1992 1110 1116
50. H. Tohgi, T. Abe, S. Takahashi, J. Takahashi, and H. Hamato Concentrations of serotonin and its related substances in the cerebrospinal fluid of Parkinsonian patients and their relations to the severity of symptoms Neurosci. Lett. 150 1993 71 74
51. T. Torda, I. Yamaguchi, F. Hirata, I.J. Kopin, and J. Axelrod Mepacrine treatment prevents immobilization-induced desensitization of beta-adrenergic receptors in rat hypothalamus and brain stem Brain Res. 205 1981 441 444
52. C.F. Valenzuela, J.A. Kerr, and D.A. Johnson Quinacrine binds to the lipid-protein interface of the Torpedo acetylcholine receptor: a fluorescence study J. Biol. Chem. 267 1992 8238 8244
53. S.S. Vogel, E.A. Leikina, and L.V. Chernomordik Lysophosphatidylcholine reversibly arrests exocytosis and viral fusion at a stage between triggering and membrane merger J. Biol. Chem. 268 1993 25764 25768
54. A.C. Williams, H.S. Pall, G.B. Steventon, S. Green, S. Buttrum, H. Molloy, and R.H. Waring N-methylation of pyridines and Parkinson's disease Adv. Neurol. 60 1993 194 196
55. Y. Xu Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction Biochim. Biophys. Acta 1582 2002 81 88
56. Y. Yuan, S.M. Schoenwaelder, H.H. Salem, and S.P. Jackson The bioactive phospholipid, lysophosphatidylcholine, induces cellular effects via G-protein-dependent activation of adenylyl cyclase J. Biol. Chem. 271 1996 27090 27098